Ignite Creation Date:
2024-05-06 @ 2:13 PM
Last Modification Date:
2024-10-26 @ 1:26 PM
Study NCT ID:
NCT04243616
Status:
RECRUITING
Last Update Posted:
2024-02-06
First Post:
2020-01-24
Brief Title:
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
Sponsor:
Organization:
Medical College of Wisconsin